Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.

Ajay K NookaUma ShanmugasundaramNarayanaiah CheedarlaHans VerkerkeVenkata-Viswanadh Edara Rajesh M Valanparambil Jonathan L Kaufman Craig C Hofmeister Nisha S JosephSagar LonialMaryam AzeemRenee Julia Manalo Jeffrey M Switchenko Andres Chang Susanne L Linderman John D Roback Kavita M Dhodapkar Rajesh M Valanparambil Mehul S SutharAndrew S NeishMadhav V Dhodapkar

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

These data show that vaccine-induced antibodies in several patients with MM lack detectable virus-neutralizing activity. Vaccine-mediated induction of nAbs is affected by race, disease, vaccine, and treatment characteristics. These data have several implications for the emerging application of booster vaccines in immunocompromised hosts.

Keyphrases

sars cov
electronic health record
big data
dengue virus
multiple myeloma
diabetic rats
respiratory syndrome coronavirus
zika virus
newly diagnosed
combination therapy
drug induced
coronavirus disease
endothelial cells
acute respiratory distress syndrome
replacement therapy